Clinical Data AZ is three for three with COPD hope tozorakimab PharmaphorumAstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.Clinical DataRespiratoryRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story Post navigation Previous: Trump backs psychedelics for mental health in new executive orderNext: The Omnichannel Gap: Building the CRM of the Future for Patient Services Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
